Transcription of 2.07 Protocol Name: CHOP & Rituximab
{{id}} {{{paragraph}}}
Example: stock market
2.07 Protocol Name: CHOP & Rituximab
2 07 R- chop Version 2 0 Page 1 of 5 Protocol name : chop & Rituximab Indication Intermediate and high grade, B-cell non-Hodgkins lymphoma expressing CD20. Second or third line therapy for low grade, B cell non-Hodgkins lymphoma expressing CD20. Pre-treatment Evaluation Document histological sub-type of lymphoproliferative disorder according to WHO classification. Document disease stage clinically, including presence or absence of B symptoms. Investigations should include CT scan of chest, abdomen and pelvis, bone marrow aspirate & trephine biopsy. Document FBC (with film), U&E, creatinine, LFTs, calcium, glucose, immunoglobulin levels and a direct antiglobulin test. LDH is also required for patients with aggressive NHL. CSF cytology must be obtained for patients with aggressive NHL involving peripheral blood, testis, orbit, paranasal sinus or paraspinal area. Document WHO performance status of patient. For aggressive NHL, document International Prognostic Index (IPI) score according to NEJM 1994; 329: 987-994 Document height, weight and body surface area.
2 07 R-CHOP Version 2 0 Jul08.doc Page 1 of 5 2.07 Protocol Name: CHOP & Rituximab Indication • Intermediate and high grade, B-cell non-Hodgkins
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: